EMA — authorised 1 July 1999
- Application: EMEA/H/C/000230
- Marketing authorisation holder: GlaxoSmithKline Trading Services Limited
- Local brand name: Integrilin
- Indication: Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an earl
- Status: withdrawn